Ligand Pharmaceuticals Incorporated Company Profile (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its quarterly earnings data on Monday, August, 7th. The company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.42. The company earned $28 million during the quarter, compared to the consensus estimate of $24.40 million. Ligand Pharmaceuticals Incorporated had a net margin of 7.39% and a return on equity of 5.05%. The company's quarterly revenue was up 43.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.50 EPS. View Ligand Pharmaceuticals Incorporated's Earnings History.

Ligand Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Ligand Pharmaceuticals Incorporated.

5 analysts have issued 1 year price targets for Ligand Pharmaceuticals Incorporated's shares. Their predictions range from $104.00 to $160.00. On average, they expect Ligand Pharmaceuticals Incorporated's share price to reach $135.17 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals Incorporated.

Here are some recent quotes from research analysts about Ligand Pharmaceuticals Incorporated stock:

• 1. HC Wainwright analysts commented, "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business model.Ligand seeks out value-based acquisitions of companies and technologies that have led to both current and anticipated revenue streams, Pantginis commented in his initiation note. This has also resulted in the company's reputation of reporting sustained profitability.Ligand is also an early pioneer of contingent value rights for its acquisitions, the analyst continued. As such, earnings growth is supported by the company's increasing royalty streams that are also a "significant spreading out of risk" (9/5/2017)
• 2. According to Zacks Investment Research, "Ligand’s Captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. However, the company derives a substantial portion of its revenues from royalties associated with the sales of two products – Promacta and Kyprolis. Any setback related to either of these two products could have a substantial impact on the company’s results. Notably, Ligand obtains Captisol from a single supplier. Hence any interruption in the supply of Captisol would have an adverse effect on the company’s results. Shares of Ligand have outperformed the broader industry in the last one year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/11/2017)

Some companies that are related to Ligand Pharmaceuticals Incorporated include Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Bio-Techne Corp (TECH), ACADIA Pharmaceuticals (ACAD), PAREXEL International Corporation (PRXL), Puma Biotechnology (PBYI), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA), INC Research Holdings (INCR), Blueprint Medicines Corporation (BPMC), Sage Therapeutics (SAGE), Ironwood Pharmaceuticals (IRWD) and Intrexon Corporation (XON).

Ligand Pharmaceuticals Incorporated's management team includes the folowing people:

• Matthew W. Foehr, President, Chief Operating Officer
• John L. Higgins, Chief Executive Officer, Director
• Matthew E. Korenberg, Chief Financial Officer, Vice President - Finance
• Charles S. Berkman J.D., Vice President, General Counsel, Secretary
• John W. Kozarich, Non-Executive Independent Chairman of the Board
• Nancy Ryan Gray, Director
• Jason M. Aryeh, Independent Director
• Todd C. Davis, Independent Director
• John L. LaMattina Ph.D., Independent Director

Ligand Pharmaceuticals Incorporated's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.78%), William Blair Investment Management LLC (8.45%), Vanguard Group Inc. (8.30%), State Street Corp (3.86%), Victory Capital Management Inc. (3.23%) and Janus Henderson Group PLC (2.83%). Company insiders that own Ligand Pharmaceuticals Incorporated stock include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr and Melanie J Herman. View Institutional Ownership Trends for Ligand Pharmaceuticals Incorporated.

Ligand Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including AJO LP, State of New Jersey Common Pension Fund D, State Street Corp, FMR LLC, Elk Creek Partners LLC, Columbia Partners L L C Investment Management, Principal Financial Group Inc. and Prudential Financial Inc.. Company insiders that have sold Ligand Pharmaceuticals Incorporated stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins and Matthew W Foehr. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

Ligand Pharmaceuticals Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Russell Investments Group Ltd., Macquarie Group Ltd., Castleark Management LLC, Royal Bank of Canada, BlackRock Inc., Rice Hall James & Associates LLC and Tygh Capital Management Inc.. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

Shares of Ligand Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Ligand Pharmaceuticals Incorporated stock can currently be purchased for approximately $136.38.